Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Study sponsor: Faeth Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-09Estimated
Enrollment · participants40Estimated
Source updated2025-12-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.